Conversely, elevated cannabinoid receptor levels have been observed in certain malignancies including prostate cancer, pancreatic cancer and non-Hodgkin lymphoma [31,41], where higher CB1 expression correlates with increased disease severity and poor prognosis in prostate and pancreatic cancer [42,43]. This evidence concerns the gene CNR1 and prostate cancer.